Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 17/20 | 0.59 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL29377757 | 1.00 | IL23R (0.59) | IL23RUTS2R | |
| SCHEMBL14817785 | 0.99 | IL23R (0.59) | IL23RUTS2R | |
| SCHEMBL30710492 | 0.99 | IL23R (0.59) | IL23RUTS2R | |
| SCHEMBL7103421 | 0.99 | IL23R (0.59) | IL23RUTS2R | |
| SCHEMBL31721667 | 0.95 | IL23R (0.58) | IL23RUTS2R | |
| SCHEMBL29550921 | 0.94 | IL23R (0.64) | IL23R | |
| SCHEMBL29550887 | 0.94 | IL23R (0.64) | IL23R | |
| SCHEMBL29550452 | 0.93 | IL23R (0.61) | IL23RUTS2R | |
| SCHEMBL29550903 | 0.93 | IL23R (0.62) | IL23RUTS2R | |
| SCHEMBL30462105 | 0.92 | IL23R (0.60) | IL23RUTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144852-A1 | COMPOSITIONS AND METHODS FOR TREATING ACROMEGALY | CAMURUS AB (SE) | 2026-05-28 | — | — | US | disclosed |
| EP-4731247-A1 | COMPOSITIONS AND METHODS FOR TREATING ACROMEGALY | Camurus AB (SE) | 2026-04-29 | — | — | EP | disclosed |
| US-20250281569-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROENDOCRINE TUMORS | CAMURUS AB (SE) | 2025-09-11 | — | — | US | disclosed |
| WO-2024263085-A1 | COMPOSITIONS AND METHODS FOR TREATING ACROMEGALY | CAMURUS AB (SE) | 2024-12-26 | — | — | WO | disclosed |
| US-20240307504-A1 | INTRANASAL FORMULATIONS AND DELIVERY OF SOMATOSTATIN MIMETICS AND USES THEREOF | NBO PHARMA LLC (US) | 2024-09-19 | — | — | US | disclosed |
| EP-4333874-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROENDOCRINE TUMORS | Camurus AB (SE) | 2024-03-13 | — | — | EP | disclosed |
| EP-4297727-A1 | METHODS AND THERAPEUTIC COMBINATIONS FOR TREATING IDIOPATHIC INTRACRANIAL HYPERTENSION AND CLUSTER HEADACHES | NBO Pharma LLC (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-4281041-A1 | INTRANASAL FORMULATIONS AND DELIVERY OF SOMATOSTATIN MIMETICS AND USES THEREOF | NBO Pharma LLC (US) | 2023-11-29 | — | — | EP | disclosed |
| WO-2022182779-A9 | METHODS AND THERAPEUTIC COMBINATIONS FOR TREATING IDIOPATHIC INTRACRANIAL HYPERTENSION AND CLUSTER HEADACHES | NBO PHARMA LLC (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2022235186-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROENDOCRINE TUMORS | CAMURUS AB (SE) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022182779-A1 | METHODS AND THERAPEUTIC COMBINATIONS FOR TREATING IDIOPATHIC INTRACRANIAL HYPERTENSION AND CLUSTER HEADACHES | NBO PHARMA LLC (US) | 2022-09-01 | — | — | WO | disclosed |
| WO-2022159593-A1 | INTRANASAL FORMULATIONS AND DELIVERY OF SOMATOSTATIN MIMETICS AND USES THEREOF | NBO PHARMA LLC (US) | 2022-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281569-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROENDOCRINE TUMORS | SSTR2, SSTR5, SSTR3 | IL23R 2573/4885UTS2R 1771/4885 |
| US-20260144852-A1 | COMPOSITIONS AND METHODS FOR TREATING ACROMEGALY | SSTR2, SSTR1, IGF1R | IL23R 1325/4885UTS2R 2093/4885 |
| US-20240307504-A1 | INTRANASAL FORMULATIONS AND DELIVERY OF SOMATOSTATIN MIMETICS AND USES THEREOF | SSTR3, CRH, NPR3 | IL23R 1139/4885UTS2R 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.